- Nivolumab-cabozantinib doublet is effective as first-line treatment in advanced RCC
Choueiri TK, et al. ESMO 2020 Virtual Meeting, abstract 696O. - Trials with chemoimmunotherapy in metastatic TNBC show contradicting results
Emens LA, et al. ESMO 2020 Virtual Meeting, abstract LBA16; Miles DW, et al. ESMO 2020 Virtual Meeting, abstract LBA15. - Adjuvant osimertinib in NSCLC reduces risk of CNS recurrence
Tsuboi M, et al. ESMO 2020 Virtual Meeting, abstract LBA1. - CDK4/6 inhibitor palbociclib effective in ER+ advanced endometrial cancer
Mirza MR, et al. ESMO 2020 Virtual Meeting, abstract LBA28. - Nivolumab plus chemotherapy: new standard for first-line treatment of gastric cancer?
Möhler M, et al. ESMO 2020 Virtual Meeting, abstract LBA6; Boku N, et al. ESMO 2020 Virtual Meeting, abstract LBA7. - Lorlatinib outperforms crizotinib in ALK-positive advanced NSCLC
Solomon B, et al. ESMO 2020 Virtual Meeting, abstract LBA2.
Posted on
Table of Contents: ESMO 2020
Featured articles
COVID-19 and Cancer
Breast Cancer
Gastrointestinal Cancers
Lung Cancer
Melanoma
Genitourinary Cancers
Bladder cancer risk and early detection
Gynaecological Cancers
Basic Science
site created by:
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com